The American Journal of Gastroenterology · 2024 · 32 citations · 15 references
PharmacyPharmacotherapyClinical PharmacologyComparative Effectiveness ResearchGastrointestinal PharmacotherapyCrohn Disease PharmacotherapyGastrointestinal InflammationInflammatory Bowel DiseaseInflammatory Disease PharmacotherapyTreatment EffectivenessUlcerative Colitis PharmacotherapyComparative Effectiveness TrialsInflammatory Bowel Disease Therapy
INTRODUCTION: There are limited real-world data comparing the effectiveness of upadacitinib and tofacitinib in patients with ulcerative colitis (UC). METHODS: We conducted a retrospective cohort study using TriNetX, a multi-institutional database, to compare the effectiveness of upadacitinib and tofacitinib in patients with UC. The primary aim was to assess the risk of a composite outcome of hospitalization requiring intravenous steroids and/or colectomy within 6 and 12 months. One-to-one propensity score matching was performed for demographics, comorbid conditions, mean hemoglobin, C-reactive protein, albumin, and calprotectin, and prior UC medications including recent oral or intravenous steroid use between the cohorts. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence intervals (CI). RESULTS: There were 526 patients in the upadacitinib cohort (mean age 40.4 ± 16.3, 44.8% female sex, 76.6% White race) and 1,149 patients in the tofacitinib cohort (mean age 42 ± 17.1, 41.9% female sex, 76% White race). After propensity score matching, there was no significant difference in the risk of the composite outcome of need for intravenous steroids and/or colectomy within 6 months (aOR 0.75, 95% CI 0.49-1.09). However, there was a lower risk of the composite outcome (aOR 0.63, 95% CI 0.44-0.89) in the upadacitinib cohort compared with the tofacitinib cohort within 12 months. There was no difference in the risk of intravenous steroid use (aOR 0.70, 95% CI 0.48-1.02) but lower risk of colectomy (aOR 0.46, 95% CI 0.27-0.79). In sensitivity analysis, there was also a lower risk of the composite outcome (aOR 0.64, 95% CI 0.44-0.94), including lower risk of intravenous steroid use (aOR 0.67, 95% CI 0.45-0.99) and colectomy (aOR 0.49, 95% CI 0.26-0.92) in the upadacitinib cohort compared with the tofacitinib cohort within 12 months. DISCUSSION: This study utilizing real-world data showed that upadacitinib was associated with improved disease-specific outcomes at 12 months compared with tofacitinib in patients with UC.
15
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn, Chinyu Su, Bruce E. Sands et al. · New England Journal of Medicine · 2017 · 1.7K citations · Full text
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine · 2022 · 1.7K citations · Full text
Silvio Danese, Séverine Vermeire, Wen Zhou et al. · The Lancet · 2022 · 597 citations · Full text
Pharmacy, Oncology, Pharmacotherapy +10